Resource Library

Missed Opportunities for Healthcare Providers to Discuss HIV Preexposure Prophylaxis with People who Inject Drugs

This article from the International Journal of Drug Policy identifies missed opportunities for healthcare providers to discuss PrEP with people who inject drugs.

Service Delivery

Estimates of HIV incidence, prevalence and Canada’s progress on meeting the 90-90-90 HIV targets, 2020

This report provides an update for 2020 on Canada’s estimates of national HIV incidence and prevalence and on progress towards meeting the 90-90-90 targets set out for 2020. Reporting on these targets supports a pan-Canadian response to HIV/AIDS in which this information can be used to help provide an understanding of the effectiveness of current…

Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings

This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.

Research

More than Just Oral PrEP: Exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor

This exploratory and cross-sectional study investigated interest in four biomedical prevention tools—rectal douche, dissolvable implant, removable implant and injection—among a racially diverse sample of men who have sex with men from the Northeast Corridor region between Philadelphia and Trenton.

Research

AIDSVu

AIDSVu is an interactive online mapping tool that visualizes the impact of the HIV epidemic on communities across the United States to increase disease awareness and promote data-driven public health decision-making. This includes information on PrEP use and need from national to city level.

Monitoring & Evaluation

USA HIV National Strategic Plan A Roadmap to End the Epidemic, 2021-25

This HIV National Strategic Plan (HIV Plan) sets forth bold targets for ending the HIV epidemic in the United States by 2030. The HIV Plan articulates goals, objectives and strategies to prevent new infections, treat people with HIV to improve health outcomes, reduce HIV-related disparities, and better integrate and coordinate the efforts of all partners…

Normative Guidance/Policies

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies